Advantages of organ-sparing treatment approaches in metastatic kidney cancer
Purpose This study analyzed oncological outcomes of patients with metastatic clear-cell renal cell carcinoma (ccRCC) treated with cytoreductive partial nephrectomy or nephrectomy. Methods This prospective non-randomized cohort study included 109 patients with metastatic ccRCC who underwent surgical...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2023-07, Vol.149 (7), p.3131-3137 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3137 |
|---|---|
| container_issue | 7 |
| container_start_page | 3131 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 149 |
| creator | Vitruk, Iurii Voylenko, Oleg Stakhovsky, Oleksandr Kononenko, Oleksii Pikul, Maksym Semko, Sofiya Hrechko, Bohdan Koshel, Denis Stakhovsky, Eduard |
| description | Purpose
This study analyzed oncological outcomes of patients with metastatic clear-cell renal cell carcinoma (ccRCC) treated with cytoreductive partial nephrectomy or nephrectomy.
Methods
This prospective non-randomized cohort study included 109 patients with metastatic ccRCC who underwent surgical treatment between 2011 and 2020. Patients were stratified into cytoreductive partial nephrectomy or nephrectomy groups. Survival curves were estimated, and Cox-regression analysis was performed to identify factors affecting potential lethality.
Results
The groups differed significantly in terms of T stage and International metastatic RCC database consortium (IMDC) risk groups, but not international society of urological pathology (ISUP) grading. The average blood loss volume was higher in the partial nephrectomy group. In contrast, the duration of post-operative stay, complication rate; and 30-day hospital readmission rate were similar between two groups. There was a significant difference in overall survival in favor of the partial nephrectomy group, who had better 7-year survival rates. Standardization based on the clinical complexity of the patients showed that cytoreductive partial nephrectomy was associated with a lower risk of death compared to nephrectomy.
Conclusion
Partial nephrectomy is a safe method of choice in patients with metastatic ccRCC. Kidney preservation in a metastatic setting can play a role in reducing potential adverse systemic therapy events and in decreasing the risk for concomitant pathology deterioration. |
| doi_str_mv | 10.1007/s00432-022-04216-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2693781658</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2693781658</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-ae36b1feaf521803db225e54be89db6c6cc1414db79c224d4370d17ca82fbea33</originalsourceid><addsrcrecordid>eNp9kEtLxDAQx4Mouj6-gAcpePFSzaNpssdl8QULXvQcpul0rW7TmqTCfnuzrg_w4CGESX7zn-FHyCmjl4xSdRUoLQTPKU-n4KzMyx0yYZsnJoTcJRPKFMtl-jkghyG80FRLxffJgZBapYpPyGJWv4OLsMSQ9U3W-yW4PAzgW7fMokeIHbqYwTD4HuxzolqXdRghRIitzV7b2uE6s-As-mOy18Aq4MnXfUSebq4f53f54uH2fj5b5FYoGXNAUVasQWjSbpqKuuJcoiwq1NO6Km1pLStYUVdqajkv6kIoWjNlQfOmQhDiiFxsc9NSbyOGaLo2WFytwGE_BsPLqVCalVIn9PwP-tKP3qXtDNeCaa2pZIniW8r6PgSPjRl824FfG0bNxrXZujbJtfl0bcrUdPYVPVYd1j8t33ITILZAGDY60f_O_if2A44tiZw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2831888051</pqid></control><display><type>article</type><title>Advantages of organ-sparing treatment approaches in metastatic kidney cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Vitruk, Iurii ; Voylenko, Oleg ; Stakhovsky, Oleksandr ; Kononenko, Oleksii ; Pikul, Maksym ; Semko, Sofiya ; Hrechko, Bohdan ; Koshel, Denis ; Stakhovsky, Eduard</creator><creatorcontrib>Vitruk, Iurii ; Voylenko, Oleg ; Stakhovsky, Oleksandr ; Kononenko, Oleksii ; Pikul, Maksym ; Semko, Sofiya ; Hrechko, Bohdan ; Koshel, Denis ; Stakhovsky, Eduard</creatorcontrib><description>Purpose
This study analyzed oncological outcomes of patients with metastatic clear-cell renal cell carcinoma (ccRCC) treated with cytoreductive partial nephrectomy or nephrectomy.
Methods
This prospective non-randomized cohort study included 109 patients with metastatic ccRCC who underwent surgical treatment between 2011 and 2020. Patients were stratified into cytoreductive partial nephrectomy or nephrectomy groups. Survival curves were estimated, and Cox-regression analysis was performed to identify factors affecting potential lethality.
Results
The groups differed significantly in terms of T stage and International metastatic RCC database consortium (IMDC) risk groups, but not international society of urological pathology (ISUP) grading. The average blood loss volume was higher in the partial nephrectomy group. In contrast, the duration of post-operative stay, complication rate; and 30-day hospital readmission rate were similar between two groups. There was a significant difference in overall survival in favor of the partial nephrectomy group, who had better 7-year survival rates. Standardization based on the clinical complexity of the patients showed that cytoreductive partial nephrectomy was associated with a lower risk of death compared to nephrectomy.
Conclusion
Partial nephrectomy is a safe method of choice in patients with metastatic ccRCC. Kidney preservation in a metastatic setting can play a role in reducing potential adverse systemic therapy events and in decreasing the risk for concomitant pathology deterioration.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-022-04216-6</identifier><identifier>PMID: 35870012</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Cancer Research ; Carcinoma, Renal Cell - pathology ; Cohort Studies ; Hematology ; Humans ; Internal Medicine ; Kidney cancer ; Kidney Neoplasms - pathology ; Kidneys ; Lethality ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Nephrectomy ; Nephrectomy - methods ; Oncology ; Pathology ; Patients ; Prospective Studies ; Renal cell carcinoma ; Retrospective Studies ; Risk groups ; Standardization</subject><ispartof>Journal of cancer research and clinical oncology, 2023-07, Vol.149 (7), p.3131-3137</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-ae36b1feaf521803db225e54be89db6c6cc1414db79c224d4370d17ca82fbea33</citedby><cites>FETCH-LOGICAL-c375t-ae36b1feaf521803db225e54be89db6c6cc1414db79c224d4370d17ca82fbea33</cites><orcidid>0000-0003-3466-0552 ; 0000-0002-2847-3980 ; 0000-0002-7081-5964 ; 0000-0001-5677-8768 ; 0000-0003-1590-235X ; 0000-0002-1657-5752 ; 0000-0003-3781-3622 ; 0000-0002-7528-551X ; 0000-0002-9261-9307</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-022-04216-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-022-04216-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35870012$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vitruk, Iurii</creatorcontrib><creatorcontrib>Voylenko, Oleg</creatorcontrib><creatorcontrib>Stakhovsky, Oleksandr</creatorcontrib><creatorcontrib>Kononenko, Oleksii</creatorcontrib><creatorcontrib>Pikul, Maksym</creatorcontrib><creatorcontrib>Semko, Sofiya</creatorcontrib><creatorcontrib>Hrechko, Bohdan</creatorcontrib><creatorcontrib>Koshel, Denis</creatorcontrib><creatorcontrib>Stakhovsky, Eduard</creatorcontrib><title>Advantages of organ-sparing treatment approaches in metastatic kidney cancer</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Purpose
This study analyzed oncological outcomes of patients with metastatic clear-cell renal cell carcinoma (ccRCC) treated with cytoreductive partial nephrectomy or nephrectomy.
Methods
This prospective non-randomized cohort study included 109 patients with metastatic ccRCC who underwent surgical treatment between 2011 and 2020. Patients were stratified into cytoreductive partial nephrectomy or nephrectomy groups. Survival curves were estimated, and Cox-regression analysis was performed to identify factors affecting potential lethality.
Results
The groups differed significantly in terms of T stage and International metastatic RCC database consortium (IMDC) risk groups, but not international society of urological pathology (ISUP) grading. The average blood loss volume was higher in the partial nephrectomy group. In contrast, the duration of post-operative stay, complication rate; and 30-day hospital readmission rate were similar between two groups. There was a significant difference in overall survival in favor of the partial nephrectomy group, who had better 7-year survival rates. Standardization based on the clinical complexity of the patients showed that cytoreductive partial nephrectomy was associated with a lower risk of death compared to nephrectomy.
Conclusion
Partial nephrectomy is a safe method of choice in patients with metastatic ccRCC. Kidney preservation in a metastatic setting can play a role in reducing potential adverse systemic therapy events and in decreasing the risk for concomitant pathology deterioration.</description><subject>Cancer Research</subject><subject>Carcinoma, Renal Cell - pathology</subject><subject>Cohort Studies</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Kidney cancer</subject><subject>Kidney Neoplasms - pathology</subject><subject>Kidneys</subject><subject>Lethality</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Nephrectomy</subject><subject>Nephrectomy - methods</subject><subject>Oncology</subject><subject>Pathology</subject><subject>Patients</subject><subject>Prospective Studies</subject><subject>Renal cell carcinoma</subject><subject>Retrospective Studies</subject><subject>Risk groups</subject><subject>Standardization</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kEtLxDAQx4Mouj6-gAcpePFSzaNpssdl8QULXvQcpul0rW7TmqTCfnuzrg_w4CGESX7zn-FHyCmjl4xSdRUoLQTPKU-n4KzMyx0yYZsnJoTcJRPKFMtl-jkghyG80FRLxffJgZBapYpPyGJWv4OLsMSQ9U3W-yW4PAzgW7fMokeIHbqYwTD4HuxzolqXdRghRIitzV7b2uE6s-As-mOy18Aq4MnXfUSebq4f53f54uH2fj5b5FYoGXNAUVasQWjSbpqKuuJcoiwq1NO6Km1pLStYUVdqajkv6kIoWjNlQfOmQhDiiFxsc9NSbyOGaLo2WFytwGE_BsPLqVCalVIn9PwP-tKP3qXtDNeCaa2pZIniW8r6PgSPjRl824FfG0bNxrXZujbJtfl0bcrUdPYVPVYd1j8t33ITILZAGDY60f_O_if2A44tiZw</recordid><startdate>20230701</startdate><enddate>20230701</enddate><creator>Vitruk, Iurii</creator><creator>Voylenko, Oleg</creator><creator>Stakhovsky, Oleksandr</creator><creator>Kononenko, Oleksii</creator><creator>Pikul, Maksym</creator><creator>Semko, Sofiya</creator><creator>Hrechko, Bohdan</creator><creator>Koshel, Denis</creator><creator>Stakhovsky, Eduard</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3466-0552</orcidid><orcidid>https://orcid.org/0000-0002-2847-3980</orcidid><orcidid>https://orcid.org/0000-0002-7081-5964</orcidid><orcidid>https://orcid.org/0000-0001-5677-8768</orcidid><orcidid>https://orcid.org/0000-0003-1590-235X</orcidid><orcidid>https://orcid.org/0000-0002-1657-5752</orcidid><orcidid>https://orcid.org/0000-0003-3781-3622</orcidid><orcidid>https://orcid.org/0000-0002-7528-551X</orcidid><orcidid>https://orcid.org/0000-0002-9261-9307</orcidid></search><sort><creationdate>20230701</creationdate><title>Advantages of organ-sparing treatment approaches in metastatic kidney cancer</title><author>Vitruk, Iurii ; Voylenko, Oleg ; Stakhovsky, Oleksandr ; Kononenko, Oleksii ; Pikul, Maksym ; Semko, Sofiya ; Hrechko, Bohdan ; Koshel, Denis ; Stakhovsky, Eduard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-ae36b1feaf521803db225e54be89db6c6cc1414db79c224d4370d17ca82fbea33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cancer Research</topic><topic>Carcinoma, Renal Cell - pathology</topic><topic>Cohort Studies</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Kidney cancer</topic><topic>Kidney Neoplasms - pathology</topic><topic>Kidneys</topic><topic>Lethality</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Nephrectomy</topic><topic>Nephrectomy - methods</topic><topic>Oncology</topic><topic>Pathology</topic><topic>Patients</topic><topic>Prospective Studies</topic><topic>Renal cell carcinoma</topic><topic>Retrospective Studies</topic><topic>Risk groups</topic><topic>Standardization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vitruk, Iurii</creatorcontrib><creatorcontrib>Voylenko, Oleg</creatorcontrib><creatorcontrib>Stakhovsky, Oleksandr</creatorcontrib><creatorcontrib>Kononenko, Oleksii</creatorcontrib><creatorcontrib>Pikul, Maksym</creatorcontrib><creatorcontrib>Semko, Sofiya</creatorcontrib><creatorcontrib>Hrechko, Bohdan</creatorcontrib><creatorcontrib>Koshel, Denis</creatorcontrib><creatorcontrib>Stakhovsky, Eduard</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vitruk, Iurii</au><au>Voylenko, Oleg</au><au>Stakhovsky, Oleksandr</au><au>Kononenko, Oleksii</au><au>Pikul, Maksym</au><au>Semko, Sofiya</au><au>Hrechko, Bohdan</au><au>Koshel, Denis</au><au>Stakhovsky, Eduard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advantages of organ-sparing treatment approaches in metastatic kidney cancer</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2023-07-01</date><risdate>2023</risdate><volume>149</volume><issue>7</issue><spage>3131</spage><epage>3137</epage><pages>3131-3137</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Purpose
This study analyzed oncological outcomes of patients with metastatic clear-cell renal cell carcinoma (ccRCC) treated with cytoreductive partial nephrectomy or nephrectomy.
Methods
This prospective non-randomized cohort study included 109 patients with metastatic ccRCC who underwent surgical treatment between 2011 and 2020. Patients were stratified into cytoreductive partial nephrectomy or nephrectomy groups. Survival curves were estimated, and Cox-regression analysis was performed to identify factors affecting potential lethality.
Results
The groups differed significantly in terms of T stage and International metastatic RCC database consortium (IMDC) risk groups, but not international society of urological pathology (ISUP) grading. The average blood loss volume was higher in the partial nephrectomy group. In contrast, the duration of post-operative stay, complication rate; and 30-day hospital readmission rate were similar between two groups. There was a significant difference in overall survival in favor of the partial nephrectomy group, who had better 7-year survival rates. Standardization based on the clinical complexity of the patients showed that cytoreductive partial nephrectomy was associated with a lower risk of death compared to nephrectomy.
Conclusion
Partial nephrectomy is a safe method of choice in patients with metastatic ccRCC. Kidney preservation in a metastatic setting can play a role in reducing potential adverse systemic therapy events and in decreasing the risk for concomitant pathology deterioration.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>35870012</pmid><doi>10.1007/s00432-022-04216-6</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-3466-0552</orcidid><orcidid>https://orcid.org/0000-0002-2847-3980</orcidid><orcidid>https://orcid.org/0000-0002-7081-5964</orcidid><orcidid>https://orcid.org/0000-0001-5677-8768</orcidid><orcidid>https://orcid.org/0000-0003-1590-235X</orcidid><orcidid>https://orcid.org/0000-0002-1657-5752</orcidid><orcidid>https://orcid.org/0000-0003-3781-3622</orcidid><orcidid>https://orcid.org/0000-0002-7528-551X</orcidid><orcidid>https://orcid.org/0000-0002-9261-9307</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2023-07, Vol.149 (7), p.3131-3137 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2693781658 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Cancer Research Carcinoma, Renal Cell - pathology Cohort Studies Hematology Humans Internal Medicine Kidney cancer Kidney Neoplasms - pathology Kidneys Lethality Medicine Medicine & Public Health Metastases Metastasis Nephrectomy Nephrectomy - methods Oncology Pathology Patients Prospective Studies Renal cell carcinoma Retrospective Studies Risk groups Standardization |
| title | Advantages of organ-sparing treatment approaches in metastatic kidney cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T04%3A51%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advantages%20of%20organ-sparing%20treatment%20approaches%20in%20metastatic%20kidney%20cancer&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Vitruk,%20Iurii&rft.date=2023-07-01&rft.volume=149&rft.issue=7&rft.spage=3131&rft.epage=3137&rft.pages=3131-3137&rft.issn=0171-5216&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-022-04216-6&rft_dat=%3Cproquest_cross%3E2693781658%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2831888051&rft_id=info:pmid/35870012&rfr_iscdi=true |